StreetInsider.com News Articles

H.C. Wainwright Reiterates Buy Rating on Verastem (VSTM)

Fri, 16 Oct 2026 07:58:44 -0400

H.C. Wainwright analyst Andres Maldonado reiterated a Buy rating and $18.00 price target on Verastem (NASDAQ: VSTM).

The analyst commented: 'On October 15, GenFleet reported encouraging China-based combination data for GFH375, adding clinical support for the frontline strategy our KOLs highlighted following yesterday’s Verastem update. GFH375, the same molecule as VS-7375, was evaluated at 600 mg daily with cetuximab, producing a 44% ORR and 89% DCR in 54 previously treated CRC patients, with estimated median PFS of 7.3 months. The update improves are view on the early CRC data presented yesterday, where we remain cautiously optimistic. In 24 treatment-naïve PDAC patients,

Verastem (VSTM) PT Raised to $14 at Mizuho, 'Reaffirming Potential Best-in-Class Potential'

Thu, 15 Oct 2026 08:04:47 -0400

Mizuho analyst Graig Suvannavejh raised the price target on Verastem (NASDAQ: VSTM) to $14.00 (from $13.00) while maintaining a Outperform rating.

The analyst comments "Yesterday (10/14), VSTM reported impressive first US clinical efficacy and updated safety data for VS-7375 ('7375), its oral KRAS G12D inhibitor across various cancer settings. Across the board, the '7375 data met, and in some cases, well-exceeded our expectations — especially in the setting of pancreatic ductal adenocarcinoma/PDAC, for which VSTM now intends to initiate a pivotal P3 study by year-end. Shares closed just 3% higher (vs. 0% XBI), with upside perhaps limited by a $250mn financing

Verastem (VSTM) PT Raised to $14 at Mizuho, 'Reaffirming Potential Best-in-Class Potential'

Thu, 15 Oct 2026 08:04:47 -0400

Mizuho analyst Graig Suvannavejh raised the price target on Verastem (NASDAQ: VSTM) to $14.00 (from $13.00) while maintaining a Outperform rating.

Verastem (VSTM) PT Raised to $19 at RBC Capital

Thu, 15 Oct 2026 05:04:13 -0400

RBC Capital analyst Leonid Timashev raised the price target on Verastem (NASDAQ: VSTM) to $19.00 (from $14.00) while maintaining a Outperform rating.

The analyst comments "Yesterday, VSTM reported R&D results from their G12D at an R&D day we had the opportunity to attend. We think the drug is clearly active - with hints it can be best-in-class on efficacy in PDAC, and while tolerability concedes to zoldon, the drug is still well tolerated. While whether the totality of the profile will be meaningfully better than other G12D agents will take more data to confidently establish, we think the company has articulated

Verastem (VSTM) PT Raised to $19 at RBC Capital

Thu, 15 Oct 2026 05:04:13 -0400

RBC Capital analyst Leonid Timashev raised the price target on Verastem (NASDAQ: VSTM) to $19.00 (from $14.00) while maintaining a Outperform rating.

Form 8-K Verastem, Inc. For: Oct 14

Wed, 14 Oct 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20261014/27187933.html

Form 424B5 Verastem, Inc.

Wed, 14 Oct 2026 17:18:00 -0400

si-local-file:///var/storage/secattach/20261014/27187918.html

Form 424B5 Verastem, Inc.

Wed, 14 Oct 2026 17:14:00 -0400

si-local-file:///var/storage/secattach/20261014/27187881.html

Form 8-K Verastem, Inc. For: Oct 12

Wed, 14 Oct 2026 06:08:00 -0400

si-local-file:///var/storage/secattach/20261014/27183273.html

Verastem reports early VS-7375 trial data across multiple cancer types

Wed, 14 Oct 2026 06:04:18 -0400

Verastem Oncology (Nasdaq: VSTM) released initial efficacy and updated safety data from its ongoing TARGET-D 101 Phase 1/2 clinical trial evaluating VS-7375, an investigational oral KRAS G12D inhibitor, in patients with advanced KRAS G12D-mutated solid tumors, according to a company statement.

In metastatic pancreatic ductal adenocarcinoma (mPDAC), 22 patients treated with VS-7375 at 900 mg once daily showed a 50% confirmed objective response rate (ORR) in the second-line setting, a 41% confirmed ORR across the second-line and later population, and a 36% confirmed ORR in the third- and fourth-line setting. Two complete responses were observed. The disease control rate was 86%,

Verastem Oncology prices $250M stock and warrant offering

Wed, 14 Oct 2026 06:04:12 -0400

Verastem Oncology (Nasdaq: VSTM) has priced an underwritten public offering of common stock and pre-funded warrants expected to raise approximately $250 million in gross proceeds, according to a press release from the company.

The offering consists of 30,937,500 shares of common stock priced at $8.00 per share. Certain investors will receive pre-funded warrants to purchase up to 312,503 shares at $7.9999 per warrant, reflecting the per-share price less a $0.0001 exercise price. All securities are being sold by Verastem Oncology.

The offering is expected to close on or about October 15, 2026, subject to customary closing conditions. Gross proceeds do not account

Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

Wed, 14 Oct 2026 06:04:00 -0400

BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to the development and commercialization of new medicines to improve the lives of patients diagnosed with RAS/MAPK pathway-driven cancers, today announced the pricing of an underwritten offering of 30,937,500 shares of its common stock at an offering price of $8.00 per share, and in lieu of common stock to certain investors, pre-funded warrants to purchase up to an aggregate of 312,503 shares of its common stock at an offering price of $7.9999 per pre-funded warrant, which represents the per share offering price for the common stock less

Verastem Oncology Announces Pricing of $250 Million Offering of Common Stock and Pre-Funded Warrants

Wed, 14 Oct 2026 06:04:00 -0400

Verastem Oncology names Michael Bailey as CEO starting January 2027

Wed, 14 Oct 2026 06:03:15 -0400

Verastem Oncology (Nasdaq: VSTM) announced that Michael P. Bailey has been appointed President and Chief Executive Officer, effective January 1, 2027. Bailey will also continue to serve on the company's Board of Directors, a position he has held since May 2026.

The appointment follows the planned retirement of Daniel Paterson, who has served as President and CEO since 2023 and with the company since 2011. Paterson will remain on the Board of Directors and serve as an advisor following his departure.

Bailey brings more than 30 years of biopharmaceutical experience, including roles focused on oncology drug development and commercialization. He previously served

Verastem Oncology names Michael Bailey as CEO starting January 2027

Wed, 14 Oct 2026 06:03:15 -0400

Bailey brings more than 30 years of biopharmaceutical experience, including roles focused on oncology drug development and commercialization. He previously served

Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan

Wed, 14 Oct 2026 06:01:00 -0400

Accomplished biopharmaceutical executive Michael P. Bailey appointed President and CEO to advance Verastem’s commercial business and lead pipeline asset advancement for VS-7375, a potential best-in-class investigational oral KRAS G12D (ON/OFF) inhibitor

Daniel Paterson to retire as President and CEO following a 35-year career in the biopharmaceutical industry; will remain as an advisor and member of Verastem’s Board of Directors

BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that Michael P. Bailey has been appointed President and Chief Executive Officer (CEO), effective January 1,

Verastem Oncology Announces Planned Chief Executive Officer Transition and Succession Plan

Wed, 14 Oct 2026 06:01:00 -0400

Daniel Paterson to retire as President and CEO following a 35-year career in the biopharmaceutical industry; will remain as an advisor and member of Verastem’s Board of Directors

VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Dise

Wed, 14 Oct 2026 06:00:00 -0400

VS-7375 900 mg QD monotherapy achieved a 41% confirmed ORR in the broader 2L+ pancreatic ductal adenocarcinoma (PDAC) patient population and a 36% confirmed ORR in 3-4L; responses are durable with a majority of patients ongoing >6 months and a 67% landmark 6-month PFS rate

FDA alignment reached on Phase 3 trial design in 1L mPDAC; plan to open trial by year-end

Early results in heavily pretreated 3L+ colorectal cancer (CRC) include 33% unconfirmed ORR with 900 mg QD in combination anti-EGFR therapy with no patients with target lesion increases

VS-7375 achieved 43% confirmed ORR with 600 mg QD

VS-7375 Demonstrates Robust Anti-Tumor Activity Across Advanced KRAS G12D-Mutant Cancers, Highlighted by 50% Confirmed ORR in 2L Pancreatic Ductal Adenocarcinoma and Two Complete Responses in 2L+ Dise

Wed, 14 Oct 2026 06:00:00 -0400

VS-7375 900 mg QD monotherapy achieved a 41% confirmed ORR in the broader 2L+ pancreatic ductal adenocarcinoma (PDAC) patient population and a 36% confirmed ORR in 3-4L; responses are durable with a majority of patients ongoing >6 months and a 67% landmark 6-month PFS rate
FDA alignment reached on Phase 3 trial design in 1L mPDAC; plan to open trial by year-end
Early results in heavily pretreated 3L+ colorectal cancer (CRC) include 33% unconfirmed ORR with 900 mg QD in combination anti-EGFR therapy with no patients with target lesion increases
VS-7375 achieved 43% confirmed ORR with 600 mg QD

H.C. Wainwright Reiterates Buy Rating on Verastem (VSTM)

Thu, 08 Oct 2026 07:06:45 -0400

H.C. Wainwright analyst Andres Maldonado reiterated a Buy rating and $18.00 price target on Verastem (NASDAQ: VSTM).
The analyst commented: "A closer look of the first approved pan-RAS FDA review gives us more reason to believe VS-7375 can stand out in G12D-mutated cancers, particularly through selective inhibition and combination tolerability. Daraxonrasib clearly validates RAS inhibition in pancreatic cancer, but the underlying results show that activity varies meaningfully by mutation. In RASolute 302, confirmed ORR was 24% in G12D-mutant patients versus 50% in G12V, suggesting that the pooled G12 response rate does not fully capture the opportunity for a G12D-focused drug. The

Verastem (VSTM) PT Raised to $19 at B.Riley

Wed, 07 Oct 2026 09:03:20 -0400
B.Riley analyst Kalpit Patel raised the price target on Verastem (NASDAQ: VSTM) to $19.00 (from $16.00) while maintaining a Buy rating.

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 05 Oct 2026 16:02:00 -0400

BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 380,500 restricted stock units (RSUs) to 24 new employees and stock options to purchase 50,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price equal to $7.90, the closing price of Verastem Oncology’s common stock

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Mon, 05 Oct 2026 16:02:00 -0400

BOSTON--(BUSINESS WIRE)-- Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced the grant of 380,500 restricted stock units (RSUs) to 24 new employees and stock options to purchase 50,000 shares of its common stock to one new employee. The awards were granted pursuant to the Nasdaq inducement grant exception as an inducement material to the employee’s acceptance of employment with Verastem Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).
The stock options have an exercise price equal to $7.90, the closing price of Verastem Oncology’s common stock

BTIG Reiterates Buy Rating on Verastem (VSTM)

Mon, 05 Oct 2026 08:48:13 -0400

BTIG analyst Jeet Mukherjee reiterated a Buy rating and $18.00 price target on Verastem (NASDAQ: VSTM).
The analyst comments "We refresh our preview for VSTM's ph 1/2 TARGET-D 101
data readout for KRAS G12D inhibitor VS-7375 in PDAC, NSCLC, and CRC, scheduled
for October 14. The presentation will build on the June 2026 update and provide the
first comprehensive efficacy and safety assessment across tumor types from the US
study. With 190+ pts enrolled across cohorts, we expect a good amount to have 6+ mos
of follow-up, allowing for meaningful assessments of ORR and preliminary durability
that were absent in June.

H.C. Wainwright Reiterates Buy Rating on Verastem (VSTM)

Mon, 05 Oct 2026 06:46:28 -0400

H.C. Wainwright analyst Andres Maldonado reiterated a Buy rating and $18.00 price target on Verastem (NASDAQ: VSTM).
The analyst commented: "Over the weekend, Verastem presented new molecular analyses at IGCS that suppport the case for avutometinib plus defactinib in patients with KRAS wild-type recurrent low-grade serous ovarian cancer (LGSOC). The combination produced an 18% confirmed ORR (7/39) and 13-month median PFS in patients whose tumors lacked KRAS, NRAS, and BRAF mutations. In the smaller group with KRAS wild-type tumors harboring NRAS or BRAF mutations, ORR was 22% (2/9). The key takeaway is that activity beyond KRAS-mutant disease does not appear limited